Company intelligence / Profile preview
DMK Pharmaceuticals Corporation
San Diego, California, United Statesadamispharmaceuticals.com ↗
- Ownership
- Private
- Employees
- ~18
- Development stage
- Other
01
Overview
The company has FDA-approved products including ZIMHI (naloxone) for opioid overdose and SYMJEPI (epinephrine) for allergic reactions. They are also developing Tempol for COVID-19 treatment with over 100 subjects enrolled in Phase 2/3 trials as of February 2022, and DPI-125 for opioid use disorder.
- Therapeutic areas
- PulmonologyPsychiatryImmunologyNeurologyInfectious Diseases
- Modalities
- Small moleculesinjectable formulations
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
NIH (grant for alcohol use disorder treatment development)
Beyond the preview
Go deeper on DMK Pharmaceuticals Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMK Pharmaceuticals Corporation.